Are Glaxo's China sales reforms putting it at a commercial disadvantage?

Since Chinese officials slapped GlaxoSmithKline ($GSK) with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption there. But some in the industry say its reforms--which include eliminating sales-based compensation incentives for reps, nixing doctor speaking fees and tripling an in-house compliance team that checks every submitted receipt--could be negatively impacting its top line at a time when the company's already hurting. More

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.